SCHEMBL3072133

SCHEMBL3072133

Cc1nocc1C(=O)Nc1cnc(-c2cc(F)ccc2OC(F)(F)F)c(N)n1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 8/20 0.64
SCN5A Q14524 1/20 0.64
SCN9A Q15858 1/20 0.64
SCN2A Q99250 1/20 0.64
SCN3A Q9NY46 1/20 0.64
CSNK1D P48730 4/20 0.39
CSNK1E P49674 4/20 0.39
ABL1 P00519 2/20 0.36
DHODH Q02127 1/20 0.35
SORT1 Q99523 1/20 0.35
PDE10A Q9Y233 1/20 0.35
KIT P10721 1/20 0.34
KDR P35968 1/20 0.34
FLT3 P36888 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34
ATR Q13535 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3082318 0.91 SCN10A (0.67) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL3084088 0.90 SCN10A (0.75) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL3081825 0.90 SCN10A (0.51) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL3093195 0.88 SCN10A (0.58) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL3093300 0.87 SCN10A (0.61) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL263316 0.87 SCN10A (0.81) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL3630599 0.82 SCN10A (0.64) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL3095874 0.80 SCN10A (0.60) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL3088327 0.79 SCN10A (0.52) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL3095810 0.79 SCN10A (0.59) SCN10ASCN5ASCN9ASCN2ASCN3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227872-A1 PYRAZINE DERIVATIVES KEMP MARK IAN 2010-09-09 US claimed
EP-2155727-A1 N-[6-AMINO-5-(PHENYL)PYRAZIN-2-YL]-ISOXAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NAV1.8 CHANNEL MODULATORS FOR THE TREATMENT OF PAIN Pfizer Limited (GB) 2010-02-24 EP claimed
WO-2008135830-A1 N- [6-AMINO-S- (PHENYL) PYRAZIN-2-YL] -ISOXAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NAV1.8 CHANNEL MODULATORS FOR THE TREATMENT OF PAIN PFIZER LIMITED (GB) 2008-11-13 WO claimed
US-20100227872-A1 PYRAZINE DERIVATIVES KEMP MARK IAN 2010-09-09 US disclosed
US-20100227872-A1 PYRAZINE DERIVATIVES KEMP MARK IAN 2010-09-09 US disclosed
US-20100227872-A1 PYRAZINE DERIVATIVES KEMP MARK IAN 2010-09-09 US disclosed
WO-2008135830-A1 N- [6-AMINO-S- (PHENYL) PYRAZIN-2-YL] -ISOXAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NAV1.8 CHANNEL MODULATORS FOR THE TREATMENT OF PAIN PFIZER LIMITED (GB) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227872-A1 PYRAZINE DERIVATIVES CYP3A5, TRPV5, TRPV1 SCN10A 278/4885SCN5A 13/4885SCN9A 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.